Zhejiang Hisun Pharmaceutical's Subsidiary Obtains New Veterinary Drug Registration Certificate

Stock News2025-12-18

Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that its subsidiary, Zhejiang Hisun Animal Health Products Co., Ltd., recently received the New Veterinary Drug Registration Certificate for Methylprednisolone Tablets (for canine use) issued by the Ministry of Agriculture and Rural Affairs of China. The product has been officially approved as a Class V new veterinary drug.

The approval of Methylprednisolone Tablets (for canine use) indicates that the product complies with the relevant regulations of the Veterinary Drug Administration Ordinance and the Veterinary Drug Registration Measures. This development is expected to enhance the company's strategic positioning in the veterinary drug sector and strengthen its market competitiveness.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment